key: cord-0844824-cvqgtpbw
authors: Mehdipour, Ahmad Reza; Hummer, Gerhard
title: Dual nature of human ACE2 glycosylation in binding to SARS-CoV-2 spike
date: 2020-07-09
journal: bioRxiv
DOI: 10.1101/2020.07.09.193680
sha: 27f956b528fed1d04f30afe373c46b5de1704bdd
doc_id: 844824
cord_uid: cvqgtpbw

Binding of the spike protein of SARS-CoV-2 to the human angiotensin converting enzyme 2 (ACE2) receptor triggers translocation of the virus into cells. Both the ACE2 receptor and the spike protein are heavily glycosylated, including at sites near their binding interface. We built fully glycosylated models of the ACE2 receptor bound to the receptor binding domain (RBD) of the SARS-CoV-2 spike protein. Using atomistic molecular dynamics (MD) simulations, we found that the glycosylation of the human ACE2 receptor contributes substantially to the binding of the virus. Interestingly, the glycans at two glycosylation sites, N90 and N322, have opposite effects on spike protein binding. The glycan at the N90 site partly covers the binding interface of the spike RBD. Therefore, this glycan can interfere with the binding of the spike protein and protect against docking of the virus to the cell. By contrast, the glycan at the N322 site interacts tightly with the RBD of the ACE2-bound spike protein and strengthens the complex. Remarkably, the N322 glycan binds into a conserved region of the spike protein identified previously as a cryptic epitope for a neutralizing antibody. By mapping the glycan binding sites, our MD simulations aid in the targeted development of neutralizing antibodies and SARS-CoV-2 fusion inhibitors.

Introduction S1). For each of the 11 setups, we performed 1-µs long MD simulations. In the simulations with RBDs bound to ACE2, their interaction interface remained stable throughout the simulations, as judged by the native contact profiles relative to the electron cryo-microscopy (cryoEM) structure (PDB ID 6M17) (SI Appendix, Fig. S2 ). The peptidase domain (residues 21-610) of the ACE2 receptor dimer and the RBDs are also internally stable, as judged by the root-mean-square distance (RMSD) relative to the cryoEM structure (PDB ID 6M17) (SI Appendix, Fig. S2 ). There are two dimerization interfaces between the peptidase domains of the ACE2 monomers in the complex. While the lower interface, containing an extensive network of interactions, remains stable during the simulations, the upper interface, which has only few interactions, is floppy during the simulations (SI Appendix, Fig. S3 ). Overall, the presence or absence of B 0 AT1 or the different patterns of glycosylation do not have pronounced effects on the conformations of ACE2, the RBD, and their contact interface. The N322 glycan strengthens RBD binding Geometrically, the glycans at four glycosylation sites (N53, N90, N103, and N322) have the possibility to interact with the RBD. To quantify the interactions of each glycan with the RBD, we calculated the number of residue-residue contacts between each glycan and the RBD in the six simulations where the RBD was present. Note that in each of these simulations we have two copies of the RBD-ACE2 complex, giving us 6x2=12 copies to analyze. The two glycans at positions N90 and N322 interact most strongly with the RBD ( Fig. 2A and S3) . The N322 glycan has on average between 5 and 7 interactions with the RBD in most of the simulations (in 8 out of the 12 independent RBD-ACE2 complexes) (SI Appendix, Fig. S4 ). In the remaining four complexes, inter-glycan interactions with the N546 glycan drive the N322 glycan away from the RBD (SI Appendix, Fig. S5 ). The N322 glycan is also a major interaction partner of the N343 RBD glycan on the RBD of the virus (SI Appendix, Fig. S6 ). The N322 glycan on ACE2 and the N343 RBD glycan on S have on average 1-3 interactions during the simulations. The N322 glycan has a specific binding site on the RBD The finding that the N322 glycan has the highest number of interactions with the RBD prompted us to investigate whether this glycan is binding to a particular region of the RBD. To identify the structural region of the RBD interacting with the N322 glycan, we calculated the number of residue-residue interactions between glycan monosaccharides and each residue of the RBD. The resulting interaction map pinpointed regions in the RBD involving residues 365-387 and three smaller patches near residues 406-415, 435-445, and 499-508 (Fig. 2B,C) . In these regions, the N322 glycan is interacting mainly with Y369-K378, R408, N437, N439, and V503 (Fig. 2D ). Among these residues, the N322 glycan competes with the N90 glycan for the interaction with R408 (SI Appendix, Fig. S7 ). In one of the experimental ACE2-RBD structures, this residue is in direct interaction with the N90 glycan (8) . Therefore, the presence of the N90 glycan interferes with N322 glycan binding to the RBD. The ACE2-RBD binding site has a non-polar core that is surrounded by several polar and charged residues (SI Appendix, Fig. S8 ). The interaction of the N322 glycan with the binding site is mainly governed by weak hydrogen bonds (C-H…N/O) with 6-8 interactions per complex. Polar hydrogen bonds (3-5 interactions per complex) and hydrophobic interactions (3-5 interactions per complex) also contributed significantly to the binding affinity (SI Appendix, Table S2 ). The N90 glycan interacts weakly with the bound RBD In 8 out of the 12 independent ACE2-RBD complexes in six different simulation setups, the N90 glycan had on average 2-5 interactions with the RBD, and at least some interactions in the remaining four simulations (SI Appendix, Fig. S4 ). For comparison, the two glycans at sites N53 and N103 have on average less than one interaction in all complexes. However, the N53 glycan also has occasional, transient interactions with the N343 glycan.

The simulations of ACE2 without the RBD allowed us to explore the possibility that the glycans near the RBD binding site might block ACE2-RBD binding. First, we calculated the number of interactions between the glycan at each glycosylation site and the residues involved in RBD binding, as identified in the five simulations of ACE2 in the absence of the RBD. Note that in each simulation we had two copies of ACE2, giving us altogether 5x2=10 copies to analyze. Of all glycans on ACE2, the one at the N90 position interacts most strongly with the uncomplexed RBD binding site ( Fig. 3A and S9 ). The N90 glycan has on average 1-3 interactions with the RBD in most of the simulations (in 7 out of the 10 independent RBD-ACE2 complexes). Three complexes have less than one interaction on average. In the two complexes with the lowest number of interactions, inter-glycan interactions with the N322 glycan interfere with the interactions between the N90 glycan and the RBD binding site (SI Appendix, Fig. S10 ). Second, we compared the solvent-accessible-surface area (SASA) of the binding region in ACE2 in the presence and absence of each glycan. Using different probe sizes allowed us to investigate distinct types of blocking. Smaller probes (1.4 Å) detect the regions in the binding site that are in a direct contact with the glycan, whereas larger probes identify regions shielded by the glycan without direct interactions and they are a better measure to check the accessibility of large molecules such as antibodies to the region. The glycans are covering on average 6.1% (3.8-12.2%), 25.6% (16.3-32.0%), and 41.4% (32.1-54.6%) of the binding site based on SASA calculations using probe sizes of 1.4, 5, and 10 Å, respectively (SI Appendix, Fig. S11 ). The N90 glycan is the main glycan blocking the binding site, covering 4.6% (2-8.5%), 19 .1 (5.5-31.9%), and 27.4 (13.6-45.0%), respectively, for the three probe sizes (Fig. 3B ,C and S12-14).

The N322 glycan has a lower number of interactions with the binding site and does not cover the binding site according to the SASA calculations. The only exception is the simulation with heterogonous glycan 1 (HT_WoRBD_WoBAT system), in which the N322 glycan covers a patch of the binding site comprised of residues E37, Y41, K353, and D355. Considering the potential overlap between the glycans and the bound RBD, we noticed that in most of the 10 uncomplexed ACE2 molecules, the N90 glycan has a considerable overlap with a superimposed RBD, especially near the binding interface ( Fig. 3D and S15). We conclude from this overlap that the N90 glycan interferes with RBD binding by blocking the interface.

Viral and human proteins exposed at the outer surface of virions and cells, such as SARS-CoV-2 spike and human ACE2, are heavily glycosylated. However, on reconstituted proteins used for in-vitro experiments, glycosylation is typically lacking entirely or not matching the in-situ pattern. Therefore, without detailed chemical and structural knowledge of the in-situ glycan coat, the effect of glycosylation on complex formation is often ignored in modeling. MD simulations allow us to address this challenge and to explore the effects of a variable glycan coat on protein-protein interactions.

Here we performed MD simulations of the fully glycosylated ACE2 receptor bound to the RBD of SARS-CoV-2 spike as well as unbound. These simulations gave us a detailed picture of the role of ACE2 glycans in the binding of the SARS-CoV-2 spike protein. The simulations showed contrasting effects of ACE2 glycosylation, weakening the binding of SARS-CoV-2 spike in case of the N90 glycan, strengthening the binding in case of the N322 glycan, and neutral in case of other sites.

The protective effect of the N90 glycan seen in our simulations is consistent with reports in the literature on infectivity dependence on human genetic variants. Studies after the SARS outbreak in 2003 showed that the N90 glycosylation might reduce infectivity (17). A recent deep mutational analysis demonstrated that any mutation in N90 and T92 is increasing the binding affinity for the SARS-CoV-2 spike protein (18). Based on an analysis of human ACE2 polymorphism, T92I is among the human ACE2 variants that were predicted to increase susceptibility (19) . ACE2 sequence comparison among species shows that several species including ferret, civet, and pig without an N90 glycosylation site can bind efficiently to the spike protein (SI Appendix, Fig. S1 ). Interestingly, if four residues at the N90 glycosylation site (residue 90-93) from the civet sequence are introduced into human ACE2, the SARS-CoV spike protein binds substantially more efficiently to the human receptor (17).

By contrast, the N322 glycan is crucial for RBD binding. In fact, almost all mutations removing this glycosylation site are detrimental to the binding of the RBD (18). Interestingly, mouse and rat are among the species where SARS-CoV-2 and SARS-CoV do not bind via the ACE2 receptor (6, 17, 20) . Mutations at the murine and rat 322 position (H and Q in mouse and rat respectively) do not permit glycosylation at this site (SI Appendix, Fig. S1 ). The only exception is pangolin, where the ACE2 receptor can efficiently bind to the spike protein (20) whereas the N322 position is mutated and cannot be glycosylated. Our MD simulations show that the N322 glycan is binding into a well-defined region in the RBD with a core of the residues 369-378. Comparison of the RBD sequences among different CoV viruses shows that the identified binding site is mostly conserved (Fig. 4A) .

We also explored the effect of spike glycosylation on ACE2 binding. Indeed, antigen glycosylation governs host immune responses. In the case of SARS-CoV-2, the glycans are covering almost the entire surface of the spike protein, suggesting that the virus can avoid the host immune system in a stealth fashion. In this sense, the absence of the N370 glycosylation site in the RBD of SARS-CoV-2 compared to SARS seems perplexing, as this mutation leaves a patch of the RBD exposed as a target for host immunological responses (Fig. 4A ). Simulating the RBD CoV2 with a glycan at N370 shows that the N370 RBD glycan interacts with the same core of residues (Y369-K378) as the N322 glycan (Fig.  4B ). 

The site on the RBD binding the N322 glycan, as seen in our simulations, is a prime target for neutralizing antibodies. First, this region contributes positively to the binding of the spike protein and, second, in contrast to the SARS-CoV, this region is not covered by a glycan and presumably exposed to the solvent (at least in some conformations of the spike protein). The recent hunt for neutralizing antibodies against the SARS-CoV-2 spike protein revealed a presumably cryptic epitope in the RBD targeted by a class of antibodies. Remarkably, this cryptic epitope is the same region that our MD simulations revealed as the binding site for the N322 glycan. An antibody (CR3022), which has been obtained from a convalescent SARS-CoV infected patient, has a binding site that overlaps significantly with that of the N322 glycan in our simulations (Fig. 4C ) (21) . Intriguingly, the lower affinity of 

for CR3022 is associated with the absence of the N370 RBD glycan. The VHH-72 antibody developed for RBD CoV has a similar binding site as CR3022 (Fig. 4D ) (22) . This antibody is mainly interacting with Y356 CoV (Y369 CoV2 ), S358 CoV (S371 CoV2 ), K365 CoV (K378 CoV2 ), C366 CoV (C379 CoV2 ), R426 CoV (N439 CoV2 ), and Y494 CoV (Y508 CoV2 ), most of which interact with the N322 glycan in the RBD CoV2 . Both antibodies have a suboptimal affinity for RBD CoV2 , as they were raised against RBD CoV . This shows the need for developing neutralizing antibodies targeting specifically RBD CoV2 . Therefore, details of the interactions between the N322 glycan and this epitope are central for a rational design of antibodies.

In conclusion, we established a molecular picture for the role of ACE2 glycosylation in the binding of the SARS-CoV-2 that provides mechanistic insights. We hope that our findings can serve as a basis for the rational development of neutralizing antibodies and small molecules that target the N322-glycan binding site in the RBD of the SARS-CoV-2 spike protein, and possibly of small molecules that mimic the protective effect of the N90-glycosylation variant on human ACE2.

The coordinates of the ACE2 complex were taken from PDB ID: 6M17(9) re-refined by Tristan Croll. The complex contains a dimer of the ACE2 receptor in complex with the RBD and also the B 0 AT1 transporter. The ACE2 receptor was simulated in the dimeric form and in the absence or presence of the RBD and also the B 0 AT1 transporter in different simulation setups (See SI Appendix, Table S1 ).

Based on the cryoEM structure of the complex, the ACE2 receptor, the RBD, and the B 0 AT1 transporter contain seven (N53, N90, N103, N322, N432, N546, N690), one (N343), and five (N158, N182, N258, N354, N358) N-glycosylation sites, respectively. We considered five glycosylation patterns in the simulations (See Fig. 1 and SI Appendix, Table S1 ). Two zinc ions in the peptidase binding sites of ACE2 were retained during the simulations. In two sets of systems, the glycosylation sites in the ACE2 receptor and the B 0 AT1 transporter were uniformly glycosylated with either a complex N-glycan or a high mannose N-glycan (the homogenous glycosylation patterns in Fig. 1) . In three sets of systems, each site in the ACE2 receptor was glycosylated with the most frequent N-glycan based on the MS data (13) (the heterogeneous glycosylation patterns in Fig. 1 ). In the heterogeneous glycosylated systems, an O-glycosylated site (T730) was also glycosylated based on the MS data (13) (the heterogeneous glycosylation patterns in Fig. 1) . The glycan at the glycosylation site in the RBD (N343) was added based on the MS analysis of the SARS-CoV-2 spike protein (14).

The interaction of the ACE2 receptor with the RBD of the spike protein was studied with all-atom explicit solvent MD simulation using GROMACS v2019.6 (23). The lipid bilayers of palmitoyl oleoyl phosphatidyl-choline (POPC), palmitoyl oleoyl phosphatidyl-ethanolamine (POPE), palmitoyl oleoyl phosphatidyl-serin (POPS), palmitoylsphingomyelin (PSM), and cholesterol lipids were created using the CHARMM-GUI webserver (24) . Lipid ratios are listed in SI Appendix, Table S3 . These systems were solvated with water and 150 mM NaCl, resulting in boxes of ~21×21×26 nm 3 (~1,000,000 atoms). After 2,000 steps of steepest descent energy minimization, the membrane patch was equilibrated first for 1 ns of MD simulation in an NVT ensemble with a 1-fs time step and then in an NPT ensemble (7.5 ns) with a 2-fs time step using a Berendsen thermostat and barostat (25) . Production simulations of 1 µs each were run with a 2-fs time step at a temperature of 310 K and a pressure of 1 bar in an NPT ensemble using a Nosé-Hoover thermostat (26) and a semi-isotropic Parrinello-Rahman barostat (27) with a characteristic time of 5 ps and a compressibility of 4.5×10 -5 bar -1 .

The all-atom CHARMM36m force field was used for protein, lipids and ions, and TIP3P was used for water molecules (28, 29) . The MD trajectories were analyzed with Visual Molecular Dynamics (VMD) (30) and MDAnalysis package (31) .

We performed MD simulations of an isolated RBD (chain F of PDB ID 6M17) glycosylated at positions N343 RBD and N370 RBD . For this system, we used the homogenous complex glycan (Fig. 1B  left panel) . The RBD was solvated with water and 150 mM NaCl, resulting in boxes of ~12.5×12.5×12.5 nm 3 (~84,000 atoms). After 2,000 steps of steepest descent energy minimization, the system was equilibrated first for 0.5 ns of MD simulation in an NVT ensemble with a 1-fs time step and then in an NPT ensemble (8.5 ns) with a 2-fs time step using a Berendsen thermostat and barostat (25) . Production simulations of 1 µs each were run with a 2-fs time step at a temperature of 310 K and a pressure of 1 bar in an NPT ensemble using a Nosé-Hoover thermostat (26) and an isotropic Parrinello-Rahman barostat (27) with a characteristic time of 5 ps and a compressibility of 4.5×10 -5 bar -1 .

A pair of residues (θ i and θ j ) was considered being in contact when at least one pair i and j of heavy atoms belonging to θ i and θ j , respectively, was within 3.5 Å in distance. For a hydrogen bond, two geometrical conditions had to be fulfilled: 1) The D-H...A distance had to be lower than 3.4 Å and 2) the D-H...A angle had to be higher than 120°, with D and H the donor and acceptor atoms, respectively. For a hydrophobic interaction, two C or S atoms had to be within 4 Å of each other.

Following Best et al. (32) , two heavy atoms i and j are considered to form a native contact if their distance r ij 0 in the cryoEM structure is less than 4.5 Å. We then defined the fraction of native contacts Q(X) in a configuration X as Figure S4 . Interaction between the ACE2 glycans and the RBD. Number of residue-residue contacts is shown for all seven glycosylation sites for different glycosylation patterns (See Table S2 ). Table S2 ) for those simulations performed in the presence of the RBD. Figure S6 . Interaction between the ACE2 glycans and the N343 glycan of the RBD. Number of residueresidue contacts is shown between 4 glycosylation sites in ACE2 near the RBD and the N343RBD glycan for different glycosylation patterns (See Table S2 ). Figure S7 . Interaction between the N90 glycan and the RBD. Average number of residue-residue contacts is shown between the N90 glycan and the RBD residues. The main interaction region is highlighted. Figure S9 . Interaction between the ACE2 glycans and the RBD binding site. Number of residue-residue contacts is shown for all seven glycosylation sites for different glycosylation patterns (See Table S2 Table S2 ) for those simulations performed in the absence of the RBD. Table S1 . Description of the different simulations performed in this study. Table S2 . Interaction between the N322 glycan with the putative binding site in the RBD. a standard deviation. 

Y N T N I T E E N V Q N Y N T N I T E E N A Q K Y N T N I T E E N A Q K Y N T N I T E E N V Q N Y N T N I N D E N V Q K I N T N I T D E N I Q K Y N T N I T D E N V Q K N T N I T E E N V Q N Y N T N I T D E N A K N Y N T N I T D E N I Q K Y N T N I T D E N V Q K

A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

Angiotensin-converting enzyme 2 as a therapeutic target for heart failure

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Structural basis of receptor recognition by SARS-CoV-2

Human ACE2 receptor polymorphisms predict SARS-CoV-2 susceptibility

Broad and differential animal ACE2 receptor usage by SARS-CoV-2

A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV

Structural basis for potent neutralization of betacoronaviruses by singledomain camelid antibodies

GROMACS: High performance molecular simulations through multilevel parallelism from laptops to supercomputers

CHARMM-GUI Membrane Builder toward realistic biological membrane simulations

Molecular dynamics with coupling to an external bath

Canonical dynamics: Equilibrium phase-space distributions

Polymorphic transitions in single crystals: A new molecular dynamics method

Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone phi, psi and side-chain chi(1) and chi(2) dihedral angles

Update of the CHARMM all-atom additive force field for lipids: validation on six lipid types

VMD: visual molecular dynamics

MDAnalysis: a toolkit for the analysis of molecular dynamics simulations

Native contacts determine protein folding mechanisms in atomistic simulations

T-Coffee: a web server for the multiple sequence alignment of protein and RNA sequences using structural information and homology extension

We thank Mateusz Sikora, Florian Blanc, and Sören von Bülow for their help during system setup and analysis. This work was supported by the Max Planck Society and the German Research Foundation (SFB 807 -Membrane Transport and Communication).